Dear Colleagues at #ASCO26 @OncoAlert 🚨Straight from the podium to your Feed, Proud to have @AarmstrongDuke 🇺🇸from Duke Cancer Institute discussing: Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP). Just presented at #ASCO26 The phase II CHAMP trial demonstrated promising activity of cabazitaxel, carboplatin, ipilimumab, and nivolumab in metastatic neuroendocrine and aggressive-variant #ProstateCancer . The regimen achieved a 78% 6-month radiographic PFS rate and median rPFS of 12 months, outperforming historical platinum chemotherapy benchmarks, with manageable toxicity and durable responses in select patients. @AarmstrongDuke @DrLaurenFHoward @DrChrisHoimes @LandonBrownMD @cnsternberg @aaparicioMD @BSiddiquiMD @Daniel_J_George Ping OncoAlert Faculty @montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin @yekeduz_emre @DrYukselUrun @scocmem @AmandaNizamMD @weoncologists